For a while, Risperdal seemed to be the solution to a very challenging problem. Young men and boys with bipolar disorder and schizophrenia were finding greater relief from their symptoms than they had experienced with any other medication. In addition to treating these disorders, Risperdal also proved effective at reducing aggressive behavior and irritability in children with autism. Unfortunately, as time passed, some very serious side effects began to appear.
The most disturbing of these side effects is the enlargement of male breasts, a condition known as gynecomastia. As troubling reports of serious, and often traumatic, side effects began to rise, so did Risperdal lawsuits.
Risperdal is a potent second-generation antipsychotic drug that was approved by the FDA in 1993 (and again in 2006 with Invega) to treat schizorisperdal lawsuit settlement loans fundingphrenia. The drug is manufactured and marketed by Janssen Pharmaceutical, a sister company of Johnson & Johnson—one of the largest pharmaceutical companies in the world. You can find the latest new on lawsuit for Risperdal and information from the authority on drug interactions and side effects, Drug Dangers.
Risperdal was a cash-cow for Johnson & Johnson, bringing in billions of dollars in profits for the company. To increase those profits even more, J&J’s Janssen Pharmaceutical began advertising Risperdal for off-label uses in children. The FDA never approved the drug for such uses as described by Janssen, which ultimately landed them in hot waters with authorities.
Thousands of product liability lawsuits are pending throughout the United States on behalf boys and young men who have been diagnosed with male breast growth from Risperdal use as a child.
While a number of juries have ordered Johnson & Johnson to pay substantial damages for failing to warn about the risk of Risperdal problems, a growing number of cases continue to be filed and the litigation is far from over.
Most of the current Risperdal litigation is pending in the Philadelphia Court of Common Pleas in Pennsylvania, where a small group of cases are going before juries as part of a bellwether trial process and a handful of Risperdal settlements have been reached in certain cases.
Early trials being held in select cases are designed to help gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation, went before a Pennsylvania jury. Following evidence that suggested that Johnson & Johnson’s Janssen unit knew about the risk of gynecomastia from Risperdal as early as 2001, a jury in February 2015 awarded $2.5 million in damages to a 20 year old man who started using the drug for autism when he was 8 years old.